DuPont is in a medium-term downtrend that is masking a still-positive longer-term trend. The stock is up 29.72% over the past year but has fallen 12.04% in the last month and 12.29% over three months, and at $126.99 it sits only about 53% of the way up its 52-week range of $92.49 to $157.98. That positioning is neither a momentum breakout nor a deep-value washout: the shares have surrendered a large share of their annual gains and are trading roughly 19.6% below the 52-week high, which suggests the market is repricing the growth outlook rather than simply consolidating. The 1-year gain of 29.72% versus the S&P 500's 16.22% shows DuPont was a clear relative winner over twelve months, but the recent slide has put that leadership at risk. Recent momentum is decisively negative and diverging from the longer-term uptrend. The 1-month change of -12.04% and 3-month change of -12.29% are nearly identical, indicating a steady, persistent decline rather than a single sharp shock, while the 6-month change of -5.72% and YTD gain of just 3.57% confirm that most of the past year's advance was earned in the first half of the period. Relative strength tells the same story: DuPont has underperformed SPY by 10.98 percentage points over one month, 15.33 points over three months, and 21.12 points over six months, even though it still leads by 13.50 points over twelve months. With a short ratio of 2.92 and volume of roughly 862,000 shares, there is no evidence of a squeeze dynamic; the selling looks like genuine de-risking, and the stock's failure to stabilize near $127 despite the broader market being down only 1.06% in the past month is a notable warning sign. Key levels are well defined. Support sits at the 52-week low of $92.49, roughly 27% below the current price, while resistance is the 52-week high of $157.98, about 24% above; a decisive break below the recent $127 area would open the door to a retest of the low-$120s and potentially the $92.49 floor, whereas reclaiming $140-$145 would be the first evidence of a trend reversal. The beta of 1.085 means DuPont is only about 8.5% more volatile than the market, so the recent 12% monthly decline is not explained by high beta alone, and the maximum drawdown of -17.85% shows the stock has already experienced a meaningful peak-to-trough correction. For risk management, the combination of a 1.085 beta and a 24% gap to resistance argues for smaller position sizing until price action confirms a bottom.

DuPont's revenue trajectory is contracting sharply on a reported basis, which is the single most important fundamental issue in the current data set. The most recent quarter (Q1 2026, ended March 31, 2026) generated revenue of $1.681 billion, down 45.17% year over year from $3.066 billion in Q1 2025, and the sequential trend is equally stark: revenue fell from $3.257 billion in Q2 2025 to $3.072 billion in Q3 2025, then to $1.693 billion in Q4 2025, and $1.681 billion in Q1 2026. This step-down is consistent with major portfolio divestitures rather than pure demand collapse, since segment data shows Electronics and Industrial at $1.506 billion and Water and Protection at $1.359 billion, with a Corporate segment of $227 million, and the company's own description emphasizes healthcare and water as the profit engines. The critical question for the investment case is whether the remaining businesses can grow organically fast enough to offset the lost revenue base; the raised guidance and pricing-power narrative from the May 2026 earnings release suggest management believes they can, but the reported numbers have not yet demonstrated it. Profitability is positive on an adjusted basis but negative on a trailing GAAP basis, creating a confusing picture. Q1 2026 net income was $161 million with EPS of $1.17, a gross margin of 35.81%, and an operating margin of 11.06%, which is a healthy sequential improvement from Q4 2025's net loss of $126 million and 31.13% gross margin. However, the trailing figures are weighed down by prior losses, including a Q1 2025 net loss of $589 million and a Q4 2025 net loss of $126 million, leaving trailing EPS at -$0.046, net margin at -11.37%, and ROE at -5.60%. The gross margin of 30.25% in the valuation data versus 35.81% in the most recent quarter shows the drag from weaker periods, and the operating margin of 12.56% is respectable for specialty chemicals but not exceptional; the key positive is that Q1 2026's 35.81% gross margin and $602 million gross profit indicate the core business can earn solid margins when charges are absent. The balance sheet is the strongest part of the fundamental story. Debt-to-equity is just 0.229, the current ratio is 2.42, and the company holds $752 million in cash against a market cap of roughly $16.8 billion, giving it substantial liquidity and low leverage. Free cash flow on a trailing basis is $1.107 billion, and Q1 2026 free cash flow was $130 million on operating cash flow of $232 million against $102 million of capex, while the company paid down $4.074 billion of debt in Q4 2025 and repurchased $500 million of stock in that quarter. The dividend yield of 3.56% is attractive, but the payout ratio of -76.64% reflects the trailing GAAP loss and is not sustainable on a GAAP basis; on adjusted earnings, the dividend looks far better covered. Overall, DuPont generates enough cash to fund capex and dividends internally, and the low debt-to-equity of 0.229 means financial risk is modest, but the negative ROE of -5.60% and ROA of 2.07% show that capital returns are currently depressed by charges and the shrinking revenue base.